Acute myeloïde leukemie (AML)
HOVON 156: A phase 3, multicenter, open-label, randomized study of gilteritinib versus midostaurin in combination with induction and consolidaton therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy
Myelodysplastisch syndroom (MDS)
IMerge 2: A study to evaluate imetelstat (GRN163L) in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment
Myeloproliferatieve neoplasieën (MPN)
FREEDOM 2: A phase III, multi center, open-lable, randomized study to evaluate the efficacy and safety of fedratinib compared to best avaiable therapy in subjects with DIPSS-intermediate or high-risk primary myelofibrosis, post-polycytemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib
Supportive care
REDDS2: A randomised feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes
CLARITY: Cardiotoxicity and other late effects after radiotherapy and immuno-chemotherapy for non-Hodgkin lymphoma
DUET2: Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial
Hemoglobinopathie
SCORE: Sickle cell outcome research
SICKLE CELL SCREEN: Investigating red blood cell deformability of sickle cell patients before and after the start of therapy
Ga terug naar de algemene homepage Studieinformatie.